Skip to main content

8-K

Cocrystal Pharma, Inc. (COCP)

8-K 2020-06-15 For: 2020-06-09
View Original
Added on April 06, 2026

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549


FORM8-K


CURRENTREPORT


Pursuantto Section 13 or 15(d) of The Securities Exchange Act of 1934


Dateof Report (Date of earliest event reported): June 9, 2020

CocrystalPharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-38418 35-2528215
(State<br> or other Jurisdiction<br><br> <br>of<br> Incorporation) (Commission<br><br> <br>File<br> Number) (IRS<br> Employer<br><br> <br>Identification<br> No.)
19805<br> N. Creek Parkway<br><br> <br>Bothell,<br> WA 98011
--- ---
(Address<br> of principal executive offices) (Zip<br> Code)

Registrant’s telephone number, including area code: (786) 459-1831

(Former name or former address, if changed since last report.):

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common<br> Stock COCP The<br> Nasdaq Stock Market LLC <br><br> (The Nasdaq Capital Market)

Item5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2020, the 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”) was held. At the 2020 Annual Meeting, the Company’s stockholders voted on (i) the election of five members of the Company’s Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1), and (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 (Proposal 2), as described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2020.

Set forth below are the voting results on each matter submitted to the stockholders at the 2020 Annual Meeting.

Proposal

  1. The Company’s stockholders voted to elect the following five individuals as directors to hold office until the next annual meeting of stockholders:
Nominee Votes For Votes Withheld Broker<br><br> Non-Votes
Dr. Gary Wilcox 14,611,420 11,316,974 15,214,675
Dr. Phillip Frost 14,557,109 11,371,285 15,214,675
Mr. Roger Kornberg 14,571,489 11,356,905 15,214,675
Mr. Steven Rubin 11,456,705 14,471,689 15,214,675
Dr. Anthony Japour 25,812,820 115,574 15,214,675

All five nominees were elected as directors.

Proposal 2. The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

Votes For Votes Against Abstentions
37,659,301 1,163,991 2,319,777

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cocrystal Pharma, Inc.
Date:<br> June 15, 2020 By: /s/ James Martin
Name: James<br> Martin
Title: Chief<br> Financial Officer